BACKGROUND: Information on efficacy and predictors of response to adalimumab in ulcerative colitis (UC) clinical practice is limited. AIM: Assessment of response to adalimumab and its predictors in an observational cohort study. METHODS: Retrospective cohort study based on data obtained from ENEIDA registry. All patients diagnosed with UC treated with adalimumab were included. Response to adalimumab was evaluated at weeks 12, 28, and 54 according to the partial Mayo score, and requirement of colectomy until end of follow-up. RESULTS: 48 patients with UC treated with adalimumab were included; 39 (81.3%) had previously received infliximab. Response rates at weeks 12, 28 and 54 were 70.8%, 43.2% and 35% respectively. Response to prior treatment with infliximab was the only predictive factor of response to adalimumab at week 12, which was obtained in 90% of infliximab remitters, 53.8% of responders and 33.3% of primary non-responders (p=0.01). Colectomy was required in 11 patients (22.9%), after a mean time of 205 days. The only clinical independent predictor of colectomy was non-response to adalimumab at week 12: colectomy rates were 5/34 (14.7%) in responders and 6/14 (42.9%) in non-responders (p=0.035), time free of colectomy was significantly reduced in non-responders (p=0.01). Adalimumab withdrawal due to adverse events occurred in 4.2% of patients. CONCLUSION: This study shows that adalimumab is an effective treatment in patients with UC. If used as a second anti-TNF, previous achievement of remission with the first anti-TNF predicts response, and failure to achieve response at week 12 predicts colectomy.
BACKGROUND: Information on efficacy and predictors of response to adalimumab in ulcerative colitis (UC) clinical practice is limited. AIM: Assessment of response to adalimumab and its predictors in an observational cohort study. METHODS: Retrospective cohort study based on data obtained from ENEIDA registry. All patients diagnosed with UC treated with adalimumab were included. Response to adalimumab was evaluated at weeks 12, 28, and 54 according to the partial Mayo score, and requirement of colectomy until end of follow-up. RESULTS: 48 patients with UC treated with adalimumab were included; 39 (81.3%) had previously received infliximab. Response rates at weeks 12, 28 and 54 were 70.8%, 43.2% and 35% respectively. Response to prior treatment with infliximab was the only predictive factor of response to adalimumab at week 12, which was obtained in 90% of infliximab remitters, 53.8% of responders and 33.3% of primary non-responders (p=0.01). Colectomy was required in 11 patients (22.9%), after a mean time of 205 days. The only clinical independent predictor of colectomy was non-response to adalimumab at week 12: colectomy rates were 5/34 (14.7%) in responders and 6/14 (42.9%) in non-responders (p=0.035), time free of colectomy was significantly reduced in non-responders (p=0.01). Adalimumab withdrawal due to adverse events occurred in 4.2% of patients. CONCLUSION: This study shows that adalimumab is an effective treatment in patients with UC. If used as a second anti-TNF, previous achievement of remission with the first anti-TNF predicts response, and failure to achieve response at week 12 predicts colectomy.
Authors: Carlos Taxonera; Eva Iglesias; Fernando Muñoz; Marta Calvo; Manuel Barreiro-de Acosta; David Busquets; Xavier Calvet; Antonio Rodríguez; Ramón Pajares; Javier P Gisbert; Pilar López-Serrano; José Luís Pérez-Calle; Ángel Ponferrada; Cristóbal De la Coba; Fernando Bermejo; María Chaparro; David Olivares; Cristina Alba; Ignacio Fernández-Blanco Journal: Dig Dis Sci Date: 2016-12-19 Impact factor: 3.199
Authors: Marisa Iborra; Javier Pérez-Gisbert; Marta Maia Bosca-Watts; Alicia López-García; Valle García-Sánchez; Antonio López-Sanromán; Esther Hinojosa; Lucía Márquez; Santiago García-López; María Chaparro; Montserrat Aceituno; Margalida Calafat; Jordi Guardiola; Blanca Belloc; Yolanda Ber; Luis Bujanda; Belén Beltrán; Cristina Rodríguez-Gutiérrez; Jesús Barrio; José Luis Cabriada; Montserrat Rivero; Raquel Camargo; Manuel van Domselaar; Albert Villoria; Hugo Salata Schuterman; David Hervás; Pilar Nos Journal: J Gastroenterol Date: 2016-10-08 Impact factor: 7.527
Authors: Edward Shelton; Jessica R Allegretti; Betsy Stevens; Matthew Lucci; Hamed Khalili; Deanna D Nguyen; Jenny Sauk; Cosmas Giallourakis; John Garber; Matthew J Hamilton; Michal Tomczak; Fredrick Makrauer; Robert B Burakoff; Jonathan Levine; Punyaganie de Silva; Sonia Friedman; Ashwin Ananthakrishnan; Joshua R Korzenik; Vijay Yajnik Journal: Inflamm Bowel Dis Date: 2015-12 Impact factor: 5.325